Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell T...
Theriva Biologics, Inc. (TOVX)
Company Research
Source: GlobeNewswire
ROCKVILLE, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the second Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). Cohort 2 enrolled 19 patients who received at least 1 dose of study drug (SYN-004 or Placebo randomized 2:1). Eighteen (18) patients received at least one dose of intravenous (IV) piperacillin/tazobactam and 12 of these patients completed sufficient doses of IV piperacillin/tazobactam to be evaluable towards the study endpoints. The study is ongoing and remains blinded; h
Show less
Read more
Impact Snapshot
Event Time:
TOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TOVX alerts
High impacting Theriva Biologics, Inc. news events
Weekly update
A roundup of the hottest topics
TOVX
News
- SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (???, Tokkyocho, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes [Yahoo! Finance]Yahoo! Finance
- Theriva Biologics GAAP EPS of -$6.81 [Seeking Alpha]Seeking Alpha
- Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsGlobeNewswire
- Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech GrantGlobeNewswire
- Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of RetinoblastomaGlobeNewswire
TOVX
Analyst Actions
- 11/13/24 - Maxim Group
TOVX
Sec Filings
- 11/20/24 - Form S-8
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- TOVX's page on the SEC website